Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Its goal is to develop and commercialize new t... Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.22 | 4.68085106383 | 4.7 | 5.17 | 4.4138 | 65543 | 4.75323314 | CS |
4 | 0.23 | 4.90405117271 | 4.69 | 5.34 | 4.01 | 133469 | 4.48363879 | CS |
12 | -0.04 | -0.806451612903 | 4.96 | 7.0791 | 3.198 | 193261 | 4.81350473 | CS |
26 | 0.96 | 24.2424242424 | 3.96 | 8.4 | 3.11 | 153428 | 5.35562174 | CS |
52 | -2.08 | -29.7142857143 | 7 | 20.72 | 3.11 | 105710 | 5.79648537 | CS |
156 | -2.08 | -29.7142857143 | 7 | 20.72 | 3.11 | 105710 | 5.79648537 | CS |
260 | -2.08 | -29.7142857143 | 7 | 20.72 | 3.11 | 105710 | 5.79648537 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.